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Large solutes such as high molecular weight proteins can be difficult to encapsulate in lipid vesicles. Passive trapping
of these macromolecular solutes during vesicle formation typically results in concentrations inside the vesicles that are much
lower than in the external solution. Here, we investigated the effect of macromolecular crowding on passive encapsulation of
biologicalmacromoleculeswithmolecularweightsrangingfrom52kDato660kDawithinbothindividualgiantlipidvesicles
(GVs, >3 μm diameter) and populations of 200 nm diameter large unilamellar vesicles (LUVs). Fluorescently labeled
biomacromolecules were encapsulated during vesicle formation in the presence or absence of three weight percent
poly(ethylene glycol) (PEG; 8 kDa) or dextran 500 kDa, which served as crowding agents. Encapsulation efficiency of
the labeled biomolecules was higher for the lower molecular weight solutes, with internal concentrations essentially equal to
external concentrations for labeled biomacromolecules with hydrodynamic radii (rh) less than 10 nm. In contrast, internal
concentrations were reduced markedly for larger solutes with rh g 10 nm. Addition of PEG or dextran during vesicle
formationimprovedencapsulationoftheselargerproteinsuptothesamelevelsasobservedforthesmallerproteins,suchthat
internal and external concentrations were equal. This observation is consistent with PEG and dextran acting as volume
excluders, reducing the hydrodynamic radius of the biomacromolecules and increasing their encapsulation. This work
demonstrates a simple and general route to improved encapsulation of otherwise poorly encapsulated macromolecular
solutes in both GV and LUVs up to their concentration in the solution present during vesicle formation.
Introduction
Encapsulation of biological macromolecules within lipid vesi-
cles is important for biophysical research and for a variety of
applications such as pharmaceuticals, foods, and cosmetics.
1-6
Although attractive interactions between solutes and the lipids
used to encapsulate them can lead to high encapsulation efficien-
cies, such methods are only effective for certain solute/lipid
combinations. In contrast, passive encapsulation (i.e., without
attractiveinteractions)ismoregeneralbutleadstointernalization
of solutes at or below their concentration in the vesicle formation
solution. Solute size is a key determinant in the efficiency of
passive encapsulation, with larger solutes excluded from the
vesicleinteriorsuchthattheinternalsoluteconcentrationislower
than the external concentration during vesicle formation.
1,7-9
Knowledge of solute concentrations in the vesicle interior is
important for understanding processes as varied as enzymatic
turnover, polymerization, crystallization, or phase separation
occurringinthisvolume.
4,10,11Itisalsoofinterestforapplications
in which vesicles serve as carriers for solute delivery, such as in
food formulations or therapeutics.
5,6 Quantification of encapsu-
lated solute is accomplished by different methods depending on
the size of the vesicles. Encapsulation in large unilamellar vesicles
(LUVs) and other submicrometer vesicles (SVs, which include
both LUVs and small unilamellar vesicles, SUVs) is quantified in
terms of the bulk encapsulation efficiency (BEE). BEE is the
percentage of solute trapped within a batch of submicrometer
vesicles as compared to the total amount of solute added. It is
typicallydeterminedbyremovingalloftheunencapsulatedsolute
(e.g., via centrifugation or dialysis) and then lysing the vesicles to
quantifytheremaining(encapsulated)solute.
1,9Thismethoddoes
not provide information on variability in solute encapsulation
betweenindividualvesicles.Giantvesicles(GVs,1-100μm),
12on
the other hand, are not generally studied via bulk methods due to
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their limited stability, but are large enough to be analyzed indivi-
dually.
11,13-15 For example, the concentration of a fluorescently
taggedsoluteencapsulatedwithinanindividualgiantvesiclecanbe
quantified by comparing the internal solute fluorescence to a
calibration curve.
13 The ability to determine encapsulation effi-
ciencyforindividualGVs(EEind)alsomakesitpossibletocompare
encapsulation between vesicles within a batch, which can vary
widely.
11,13-15 Recently, approaches to determination of EEind for
submicrometer vesicles have been reported; these powerful new
tools have not yet become routine.
16,17
The most common GV formation techniques, electroforma-
tion
18 and gentle hydration,
19 passively encapsulate solutes, such
thattheexpectedconcentrationinside(Cin)isequaltotheexternal
concentration during vesicle formation (Cout). For solutes with
rh < 10 nm, mean Cin does tend to be equal to Cout;h o w e v e r ,w e
and others have measured considerable variability in Cin for
individual GVs in the same batch.
13-15 Larger solutes are poorly
encapsulated. For example, mean Cin was found to be much less than
Cout for dextran polymers with hydrodynamic radius, rh >1 0n m .
14
Solute size is also an important determinant of entrapment in
submicrometer vesicles.
1,7-9 For example, Adrian and Huang
compared the encapsulation of proteins of increasing molecular
weighttothatofasmallmarkerprotein(lysozyme,14.1kDa)inca.
50 nm diameter vesicles and found decreasing trapping efficiency
withincreasingMW.The97kDaR-amylasewasencapsulatedonly
5 0 %a sw e l la st h el y s o z y m e .
7 The same authors reported that
proteins up to 120 kDa could be encapsulated in ca. 200 nm
diameter vesicles with the same trapping efficiency as sucrose.
7
BEE is often quite low for passive uptake because it is defined in
terms of the total encapsulated volume (capture volume, CV),
which can be <1% of the total volume, depending on the amount
of lipid present and the morphology of the vesicles. Although CV
can be increased up to ca. 50% by using more concentrated lipid,
20
this is not always possible for a given system. Indeed, most papers
report BEEs much less than 50%.
21-24 To increase BEE beyond
what is possible by passive encapsulation, attractive interactions
between solutes and the lipids themselves are commonly
employed.
20,22,25-27 For example, cationic lipids are routinely used
to package nucleic acid drugs, despite concerns about their toxi-
city.
27,28Soluteencapsulationbasedonelectrostaticattractionscan
be essentially complete, with nearly 100% of all solute molecules
added to the solution being associated with liposomes. Despite
excellent loading, attractive interactions with encapsulating lipids
c a nl e a dt om o r ec o m p l e xl i p o s o m emorphologies, prevent activity
of the encapsulated solute until released, and inhibit effective
release of solutes upon vesicle rupture.
1,27,29 While these factors
are often considered acceptable in drug delivery applications, it is
preferable to have free encapsulated solute of known concentration
forbiophysicalstudies,e.g.,toevaluatetheeffectsofconfinement.
30
Encapsulation of rh > 10 nm fluorescently labeled dextran
polymers in GV has been reported to improve markedly in the
presence of several weight percent additional polymeric solutes.
15
The additional polymers acted as volume excluders, resulting in
condensation of the labeled solutes and allowing them to be more
easily encapsulated during vesicle formation.
15 Macromolecular
crowding is an attractive means for improving macromolecule
encapsulation because of its generality.
31 This approach for im-
proving encapsulation has not previously been tested for bioma-
cromolecules such as proteins, which in many cases already exist in
globular conformations and hence may not undergo as large a rh
change in response to volume excluders, nor has it been tested for
encapsulationinsubmicrometervesicles.Herein,wereporttheuseof
PEG as a macromolecular crowding agent to increase the encapsu-
lation efficiency of fluorescently labeled biomacromolecules within
GVs and 200 nm diameter LUVs. We find in general that the addi-
tion of PEG increases the encapsulation efficiency of high molecular
weight (MW) biomolecules compared to those encapsulated in DI
water alone. We conclude that volume exclusion in the presence of a
crowding agent such as PEG or dextran can be used as a general
route to increase encapsulation efficiency of biomacromolecules in
bothgiantandsubmicrometerlipidvesicles,uptolevelsexpectedfor
passive encapsulation of lower MW solutes (i.e., Cin = Cout).
Results and Discussion
Volumeexclusioninducedcondensationisexpectedtohavethe
greatest impact on large, extended molecular conformations.
31,32
Therefore, the macromolecules used in this work were chosen to
give a range of molecular sizes and shapes. We first describe the
effect of polymeric volume excluders on encapsulation in GVs
formed by gentle hydration and then discuss encapsulation in
LUVs prepared by a freeze-thaw/extrusion protocol.
Effect of PEG on Biomacromolecule Encapsulation Effi-
ciency within Individual GVs (EEind). We began by encapsu-
lating fibrinogen, a 340 kDa protein with a hydrodynamic radius
(rh)of∼11nm,whichisimportantincoagulationandthrombosis
and is often administered to patients who have suffered severe
blood lossor havelostthe ability toclotblood ontheir own.
33-35
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Fibrinogen has been reported to condense to approximately one-
half of its original length during polymerization.
34,36
Fibrinogen labeled with Alexa Fluor 488 (AF488) was added
during GV formation at a concentration of 33 nM, either in DI
water or in a 3 wt % PEG 8 kDa solution. GVs were imaged
withoutremovingthemfromthehydrationsolution,suchthatthe
external fibrinogen concentration remained 33 nM. Figure 1
shows representative confocal fluorescence images and histo-
grams of encapsulation efficiency for individual GVs formed in
the presence of fibrinogen alone and coencapsulated with 3 wt %
PEG. Here, encapsulation efficiency for the individual vesicles
(EEind) is defined as the concentration ratio between the vesicle
interior (Ci) and the external solution (Co) used during vesicle
formation. The concentration ratio (Ci/Co) for each vesicle was
plottedagainstthenumberofvesiclesateachratio.Averticalline
is included at Ci/Co=1 to facilitate comparison to the external
fibrinogen-AF488 concentration. In the absence of added PEG,
encapsulation efficiency is quite poor; the GV interiors appear
dark, and fibrinogen-AF488 concentration varied considerably
fromvesicletovesicle,rangingfrom1to54nM(0.04-1.64  Co)
with a mean of 21 nM (0.64   Co). In contrast, vesicles formed in
the presence of 3 wt % PEG contained fibrinogen-AF488 con-
centrations similar to that of the external solution, with 65% of
theGVsencapsulatinginternalconcentrationsbetween28and38
nM and a mean of 34 nM.
We repeated this experiment with two other proteins having
relativelylargerhtotestthegeneralityofthemethodofincreasing
EEind via macromolecular crowding. Thyroglobulin is a 660 kDa
protein with a pIof4.6 thatisimportant in the synthesis, storage,
and secretion of thyroid hormones.
37,38 The native structure has
two slightly elongated subunits, with an rh of 10 nm.
39 In vivo,
thyroglobulin structure is known tocondensein order toincrease
the storage capacity of the thyroid.
40 Encapsulation of thyroglobulin-
AF488 (18 nM) in GVs in the absence and presence of 3 wt %
PEG 8 kDa produced results similar to those for fibrinogen-
AF488 (Supporting Information Figure 1), which had similar rh
and ability to compact. We then repeated the experiment with
catalase-AF488, a 250 kDa enzyme with a pI of 5.4 and an rh of
10.4 nm.
41,42 This protein catalyzes the decomposition of hydro-
genperoxidetowaterandoxygen,
43andhasbeenencapsulatedin
submicrometer liposomes along with superoxide dismutase and
injected to protect against oxygen toxicity in rats.
44 Images and a
histogram for Cinare shown in SupportingInformation Figure2.
Table1summarizesencapsulationresultsforeachoftheproteins.
EEind for was significantly increased vs control by addition of
PEG 8 kDa during encapsulation of all three of these relatively
large proteins (Student’s t test, p < 0.001). These results are con-
sistentwiththeroleofPEG8kDaasavolumeexcluder,drivingthe
condensation of macromolecular structures.
45-53 Proteins, nucleic
acids, and enzymes are all known to adopt condensed structures in
macromolecularly crowded solutions.
45-55 Thus, we interpret the
improved encapsulation of these high molecular weight proteins in
3 wt % PEG 8 kDa as the result of their condensation to give
reduced hydrodynamic radii, which in turn caused them to be
encapsulated as effectively as lower MW biomolecules.
WenextevaluatedtheeffectofPEG8kDaonencapsulationof
two smaller proteins and a DNA oligomer, all of which had
hydrodynamic radii less than 10 nm. R-1-antitrypsin (AAT) is a
52 kDa protein with an rh of 3.8 nm and a pI between 4.9 and
5.1.
57,58 It is responsible for inhibiting elastase in vivo, which
destroys elastin on connective tissues.
57 AAT deficiency often
leadstolungdiseases,andclinicaltrialshavebeenreportedwhere
patients are given AAT infusions, which showed beneficial
effects.
58 It has also been delivered to mice via encapsulation in
submicrometer liposomes.
59 We began by encapsulating 1.9 μM
Figure 1. (Left)Confocalfluorescenceimagesofvesiclesprepared
inthepresenceofAF488-labeledfibrinogenwithout(top)andwith
(bottom) 3wt% PEG8 kDa.Membranecompositionwas3:7egg
PC:DOPG with 0.05 mol % DOPE-rhodamine. Red represents
rhodaminefluorescence,andgreenrepresentsAF488fluorescence.
The scale bar is 20 μm. (Right) Histograms of the concentration
ratio (Cin/Cout) for encapsulation of labeled fibrinogen in indivi-
dual GVs without (top) and with (bottom) 3 wt % PEG 8 kDa
(Co =3 3n M ) .
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AAT-AF488 in GVs formed in with the presence and absence of
3 wt % PEG 8 kDa. AAT-AF488 was encapsulated at essentially
Cin = Cout with or without 3% PEG (Figure 2).
Similar results were observed for encapsulation of labeled
human serum albumin (HSA) in PEG solution as compared to
DI water (Supporting Information Figure 3). HSA has similar
characteristics as AAT (i.e., HSA has a MW of 67 kDa, pI of
4.9-5.1, and rh of3.51).
56,57 We alsostudiedthe encapsulationof
a single-stranded 173 base pair oligomer (53 kDa) labeled with
fluorescein (FAM). Nucleic acids are often encapsulated in
submicrometer vesicles for gene delivery and in GVs to study
biochemical reactions.
27,28,60 DNA is known to undergo con-
densationinthepresenceofdivalentcations, polycations,oreven
neutral polymers such as PEG.
54,55 This oligonucleotide was
sufficiently small to be effectively encapsulated in the GV even
without addition of a crowding agent (Supporting Information
Figure 4).
Table 1 compares encapsulation for each of the biomacromo-
lecular solutes with and without added PEG. In addition to the
increase in Cin for the larger proteins when encapsulated in the
presence of 3 wt % PEG, decreased heterogeneity in Cin across a
population of vesicles in a batch is suggested by the standard
deviations in Cin (Table 1) and the histograms for individual
solutes (Figures 1 and 2 and Supporting Information Figures
1-4). An F-test
61 was performed to evaluate whether differences
in the variance between the control and þ PEG populations were
statistically significant. We found statistically significant changes
in variance for the fibrinogen (p < 0.001), catalase (p <0 . 0 0 1 ) ,
andAAT(p<0.05),butnotfortheothersolutes.Theincreasein
encapsulation homogeneity when fibrinogen and catalase were
coencapsulatedwithacrowdingagentariseslargelyfromtheshift
to higher encapsulated concentrations. Decreased variance for
AAT may also be due in part to condensation, which has been
reportedforAATandothersmallpolymers,
62,63butismorelikely
due to PEG increasing the viscosity and osmotic pressure of the
solutions, as has been discussed previously.
15,64 For example,
increased viscosity could improve encapsulation heterogeneity
by facilitating pore formation in the membrane, allowing more
time for solutes to equilibrate between internal and external
solutions.
65
We note that the proteins were not foundto be associated with
the lipid membrane of the GVs, but rather to be uniformly dis-
persed in the exterior and/or interior of the vesicles (see, for
example,Figures1and2,leftpanels).Polymerizationoraggrega-
tiononmicroscopicallyvisiblelengthscaleswasalsonotobserved
for any of the biomacromolecular solutes. Preparation of the
vesiclesin3%PEGdidnotinhibittheirformationorchangetheir
size or morphology in any obvious way as compared to prepara-
tioninPEG-freesolution,consistentwithourpreviousfindingsof
Table 1. Effect of Crowding Agents on Encapsulation of Biomolecules in Giant Vesicles
solute (concentration) hydrodynamic radius (nm) crowding agent Percent theoretical EEind (%)
d
Fibrinogen
c; 340 kDa (33 nM) 11
33-35 none 64(39
3% PEG
a 104(21
3% dextran
b 101(15
Thyroglobulin
c; 660 kDa (18 nM) 10
38,39 none 67(33
3% PEG
a 100(26
Catalase
c; 250 kDa (0.13 μM) 10.4
41,42 none 53(30
3% PEG
a 106(15
R-1-Antitrypsin
c; 52 kDa (1.9 μM) 3.8
56,57 none 103(4
3% PEG
a 102(4
3% dextran
b 103(4
Human Serum Albumin
e; 67 kDa (3.3 μM) 3.5
56,57 none 107(9
3% PEG
a 98(3
173 nt ssDNA
f; 53 kDa (0.24 μM) <7.5
g none 103(10
3% PEG
a 104(5
a8 kDa.
b500 kDa.
cAlexa Fluor 488 - labeled.
dTheoretical EEind defined as the solute concentration in the external solution during vesicle
preparation,whichisgiveninparenthesesforeachsoluteinthefirstcolumn.
eFITC-labeled;
ffluorescein-labeled;
gHydrodynamicradiusof7.5nm
for 280 nt ssDNA was reported in ref 66 under conditions where excluded volume effects can be neglected; extrapolation of length vs rh data in ref 66
suggests ∼5 nm hydrodynamic radius for our 173 nt sequence.
Figure 2. (Left)Confocalfluorescenceimagesofvesiclesprepared
inthepresenceof1.9μMlabeledR-1-antitrypsinwithout(top)and
with(bottom)3wt%PEG8kDa.Membranecompositionwas3:7
eggPC:DOPGwith0.05mol%DOPE-rhodamine.Redrepresents
rhodaminefluorescence,andgreenrepresentsAF488fluorescence.
The scale bar is 20 μm. (Right) Histograms of the concentration
ratio (Cin/Cout) for encapsulation of labeled R-1-antitrypsin in
individual GVs without (top) and with (bottom) 3 wt % PEG 8
kDa (Co =1 . 9μM).
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decreasedaveragevesiclediameterat10and20wt%PEGbutno
noticeable difference between 0 and 3 wt % PEG in terms of GV
formation, size, or morphology.
15
The improvements in EEind observed in the presence of PEG
should be applicable to other crowding agents.
15 We therefore
coencapsulated fluorescently labeled fibrinogen and R-1-anti-
trypsinwith3wt%dextran500kDaforcomparison.The3wt%
dextran 500 kDa had the same effect on encapsulation as PEG
8 kDa: the higher MWprotein, fibrinogen, showed an increase in
EEindmagnitudeandhomogeneitywiththeintroductionofeither
PEG or dextran; and the lower MW protein, AAT, showed
essentially no change in mean EEind, but a decreased variance
(F-test, p < 0.05) when dextran was added (Table 1).
EffectofPEGonBulkEncapsulationEfficiency(BEE)in
Submicrometer Vesicles. Internal solute concentrations in SV
cannot be determined via simple confocal imaging as for the GV
describedabove.Therefore,weestimatedCinandtheeffectiveness
of solute encapsulation by comparing the percentage of total
solute that has been encapsulated within a batch of vesicles (bulk
encapsulation efficiency, BEE) to the capture volume. Capture
volume was estimated based onthe moles oflipid present and the
size of the vesicles, assuming unilamellarity. LUVs 200 nm in
diameter were prepared by a freeze-thaw/extrusion protocol.
BEEwasdeterminedbyremovingtheunencapsulatedsolutefrom
a batch of vesicles, then lysing the vesicles and quantifying the
remaining (encapsulated) solute. For effective passive encapsula-
tion, one can expect to achieve the same concentration inside the
vesiclesasispresentoutside(Cin=Cout).However,forhighMW
solutes, BEE is often less than the capture volume (i.e., interior
concentrations < exterior concentrations).
1,7,9
Table 2 shows the average BEE for three encapsulated solutes
(carboxyfluorescein (CF), 500 kDa dextran-FITC, and thyro-
globulin-AF488) with and without added PEG in 200 nm dia-
meter vesicles. The theoretical BEE for passive encapsulation in
this system is 0.38%, calculated by estimating the number of
vesicles formed based on the amount of lipid added to the system
(500 μM) and then calculating the volume encapsulated by those
vesiclesascomparedtotheinitialvolume.Weestimatedthatthere
were 3.4   10
5 lipid molecules per 200 nm diameter vesicle, for
4.5   10
12 vesicles that collectively encapsulated 19 μL, or 0.38%
of the total solution volume (5 mL), based on calculations for
similar systems.
1,67 Dynamic light scattering verified that vesicle
diameter remained constant whether in dilute or crowded solu-
tion, and the addition of a fluorescent lipid in the membrane
verified that a negligible amount of lipid was lost to the filter
during extrusion.
Encapsulation of the small fluorescent molecule, carboxyfluo-
rescein(CF),wasperformedasacontrol.Itwasexpectedthatthe
effect of the coencapsulation of PEG would be negligible, since
the addition of PEG did not significantly impact the encapsula-
tion efficiency of CF in GVs.
15 The change in experimental CF
BEE observed between the solutions with and without PEG was
not statistically significant based on a Student’s t test (p =0 . 6 3 )
(Table 2).
Encapsulation of FITC-dextran 500 kDa and thyroglobulin-
AF488 did show improvement for LUVs prepared in solutions
containing PEG 8 kDa as compared to solutions without PEG
(Student’s t test, p < 0.05). Experimentally determined BEE for
FITC-dextran 500 kDa and thyroglobulin-AF488 in water were
31% and 50% of the theoretically predicted value, respectively -
these low BEEs are most likely due to the large size of dextran
500 kDa (rh ∼15 nm) and thyroglobulin (rh ∼10 nm).
9,15,38,39
Additionof3wt%PEG8kDasignificantlyincreasedtheBEEof
FITC-dextran and thyroglobulin-AF488 in these vesicles, con-
sistent with condensation of the dextran and thyroglobulin struc-
turesviamacromolecularcrowding.
15Althoughtheerrorislarge,
it appears that with PEG 3%, the LUVs are essentially encapsu-
lating even these very large solutes at Cin = Cout.B E Ew a s
increased without chemically modifying the vesicle or solute to
utilize specific attractive interactions. In contrast to the GV
encapsulation data, improvements in standard deviation were
not observed in the LUV experiments. This underscores the
differenceinthetwo measurements:the errorinGVCinmeasure-
ments indicates vesicle-to-vesicle variability within a batch, while
variability in LUV BEE experiments reports on differences bet-
ween entire batches prepared separately and as such may reflect
variability in capture volume. CF BEE was less than 100% despite
its small size. We interpret this as the result of some CF loss from
the vesicle interior during centrifugation and/or other handling,
which is commonly reported in submicrometer vesicles.
69
These data are exciting, because while the majority of reports
published on BEE utilize specific interactions between liposome/
solute, this method is quite general and should apply to a variety
of solutes that can be condensed under conditions of macro-
molecular crowding. Although the absolute BEE in these experi-
ments was low, we have demonstrated that addition of 3 wt %
PEG provides a means of improving encapsulation for large
solutes such that Cin = Cout for LUVs prepared by freeze-thaw/
extrusion.Increasingtheamountoflipidusedinabatchhasbeen
shown by others to increase CV from <1% to as high as 50%;
whichwouldleadtoanincreaseinBEE,aspreviouslyreported.
20
Table 2. Bulk Encapsulation Efficiency in Submicrometer Vesicles
solute (concentration) hydrodynamic radius (nm) crowding agent % of theoretical BEE based on capture volume
a,b
Carboxyfluorescein; 376 Da (53 μM) 0.5
68
none 72(3
3% PEG 8 kDa 64(3
FITC-dextran; 500 kDa (0.82 μM) 15
9,15
none 31(18
3% PEG 8 kDa 118(46
thyroglobulin-AF488; 660 kDa (0.14 μM) 10
38,39
none 50(5
3% PEG 8 kDa 89(21
aTheoreticalBEEbasedoncapturevolume=0.38%.
bErrorsrepresentthestandarddeviationofBEEmeasurementstakenforthreeseparatebatches
of vesicles on three different days.
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Conclusions
Our results indicate that the addition of the polymeric coencap-
sulants PEG 8 kDa and dextran 500 kDa as macromolecular
crowding agents during passive encapsulation of biomacromole-
cular solutes can substantially increase mean encapsulated con-
centration and in some cases homogeneity for otherwise poorly
encapsulated high MW proteins in giant vesicles. The addition of a
crowding agent also reduced vesicle-to-vesicle encapsulation varia-
bility for the lower MW AAT, which was already encapsulated
efficiently (i.e., with Cin = Cout) in dilute solution. The mechanism
for increased encapsulation is general, such that crowding agents
need not be varied with the identity of the solute. This work is
important to those using GVs as bioreactors, where knowledge of
encapsulated concentration is critical to quantifying the progres-
sion of products formed during a reaction. Measurements of bulk
encapsulation efficiency (BEE) in LUVs in the presence of PEG
suggest that this approach works similarly in these smaller vesicles
as for GVs, bringing the internal solute concentration closer to the
external concentration such that the BEE is determined by capture
volume. The approach used here should be effective for a wide
range of membrane/macromolecular solute combinations.
Materials and Methods
ChemicalsandMaterials. L-R-Phosphatidylcholine(eggPC),
1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)](sodium salt)
(DOPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
cholesterol, and 1,2-dioleolyl-sn-glycero-3(phosphoethanolamine-
N-lissamine Rhodamine b sulfonyl) (ammonium salt) (Rhodamine-
DOPE) were purchased from Avanti Polar Lipids, Inc. (Alabaster,
AL). Carboxyfluorescein, fluorescein isothiocyanate (FITC)-
labeled and unlabeled dextrans and poly(ethylene glycol) (PEG)
were obtained from Sigma. Alexa Fluor 488 and FITC labeling
kits along with fibrinogen-Alexa Fluor 488 were purchased from
Molecular Probes, Inc. (Eugene, OR). All other proteins were
from Calbiochem (San Diego, CA). A fluorescein nucleic acid
labelingkitwaspurchasedfromMirusBio(Madison,WI).A173
nucleotide single-stranded oligomer with the sequence for influ-
enza B was purchased from Integrated DNA Technologies, Inc.
(Coralville,IA).Waterusedintheseexperimentswasdeionizedto
a resistance of18 MΩ with a NANOpure Diamond water system
from Barnstead Int. (Dubuque, IA).
Preparation of Giant Lipid Vesicles. We used the gentle
hydration method to form lipid vesicles, as previously des-
cribed.
14,15,19 Silanized borosilicate glass culture tubes, 12   75 mm,
were used to prevent biomolecules from sticking to the glass
surface duringformation (KimbleChase, Vineland,NJ).Wefirst
prepared a chloroform solution of lipids containing a 3:7 molar
ratio of egg PC:DOPG at a concentration of 0.26 mg/mL with
0.05mol%Rhodamine-DOPE.Lipidsolutionsweredriedunder
Ar (g) to form a thin, uniform lipid film, and then, the vials
were vacuum-desiccated for ∼2 h to remove any residual
organic solvent. Then, an aqueous solution containing a fluo-
rescent biomolecule with or without 3 wt % unlabeled PEG or
dextranheatedto37Cwasaddedalongthewallofthetube,and
thelipidswerehydrated48hatthistemperature.Wechose3wt%
PEG8kDabasedonpriorworkwithdextran500kDacondensa-
tion, in which we observed increased encapsulation efficiency in
GVsupto10wt%PEG,withthebulkoftheincreaseachievedby
3% and decreased average GV diameter for g10 wt % PEG.
15
Followingincubation,thesolutionswereallowedtocooltoroom
temperature.Thecontentsofthevials,whichremainedundiluted,
were removed with a micropipet and transferred to a microscope
slide silanized with N-(triethoxysilylpropyl)-o-polyethylene oxide
urethane (Gelest, Inc., Morrisville, PA) for analysis. Coverslips
were also coated with N-(triethoxysilylpropyl)-o-polyethylene
oxide urethane to prevent the adhesion of fluorescently labeled
biomolecules to the glass surface.
The concentrations of crowding agents are referred to in wt %,
since this is the common notation used for crowding agents in the
macromolecularcrowdingliterature;the3%PEG8kDausedhere
corresponds to 3.75 mM. Concentrations for fluorescently labeled
solutes,whichareconsiderablylowerthanforthecrowdingagents,
are given as molarities.
Determination of Encapsulated Solute Concentrations in
Giant Vesicles. A fluorescence line scan was taken across each
vesicle to determine the fluorescence intensity of the Alexa Fluor
488, FITC, or fluorescein inside the vesicle (Ii) and in the undiluted
bulk solution (Io, outside the vesicle), as reported previously.
14,15
The concentration of biomolecule inside (Ci) and outside (Co)t h e
GV was determined directly from the intensities (Ii, Io)b ya
calibration curve of the labeled biomolecule free in solution. From
the calibration curves, it was determined that the bulk concentra-
tion (Co) was equal to the initial concentration used to hydrate the
vesicles. A ratio of Ci/Co was taken to determine the EEind.
Microscopy. Imaging was performed using an LSM-5 Pascal
laser scanning confocal microscope from Carl Zeiss, Inc.
(Oberkochen, Germany) with a Plan-Apochromat 63  oil im-
mersion objective (1.4 NA), and Pascal software as previously
reported.
14,15Scantimewas1.97sfora512 512pixelimage.Only
vesiclesthatweregreaterthan3μmindiameter andappearedtobe
uni- or oligolamellar were analyzed.
PreparationofSubmicrometerLipidVesicles.DPPC/chol-
esterol vesicles (80:20 mol ratio) were prepared using a modified
technique provided by the distributor to yield large unilamellar
vesicles by extrusion (LUVET) as previously reported.
16,70 Briefly,
DPPCandcholesterolwerecombinedwithchloroforminaround-
bottom flask and evaporated for 4 h. Following this, 5 mL of the
soluteto be encapsulated wasadded in eitherwater or3 wt%PEG
8 kDa to yield a final lipid concentration of 0.34 mg/mL. The lipid
mixturewasallowedtoincubateinthissolutionatroomtemperature
for30min.Then,theflaskwassubjectedtofivefreeze/thawcyclesto
promoteentrapmentofwater-solublecompoundsintothevesicles.
71
The mixture was then extruded through a 0.2 μm polycarbonate
membrane for a total of 20 passes (Mini Extruder Kit, Avanti Polar
Lipids, Inc., Alabaster, AL) to yield a monodisperse suspension of
unilamellar vesicles. Excess solute was removed from the vesicle
suspension by washing with a 10000 MW dialysis cassette in DI
waterfor48h(Slide-A-Lyzer,ThermoScientific,Rockford,IL) and
then centrifuging at 16100   g, removing the supernatant, and
replacing it with a solution free of fluorescent molecules. Vesicle
diameter was confirmed using dynamic light scattering (Zetasizer
Nano S, Malvern Instruments, Worcestershire, U.K.).
Determination of Bulk Encapsulation Efficiency in Sub-
micrometer Vesicles. After centrifugation, the vesicles were
lysed in 0.5% Triton-X 100, and the encapsulated concentration
was determined via fluorescence measurements on a Jobin Yvon
Horiba FL3-21 fluorimeter.
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